1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,080 | 2,285 | 13:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11.25 | XSpray Pharma AB: Interim Report Third Quarter 2025 | 180 | GlobeNewswire (Europe) | July-September 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -47,332 thousand (-82,272)Earnings per share before dilution amounted to SEK -1.25 (-2.44)Cash flow... ► Artikel lesen | |
| 08.10.25 | XSpray Pharma AB: Xspray Pharma provides update on the FDA process for Dasynoc - observations at contract manufacturer delay approval | 232 | GlobeNewswire (Europe) | • FDA has issued a Complete Response Letter (CRL) regarding Xspray Pharma's New Drug Application (NDA) for Dasynoc, referring to GMP (Good Manufacturing Practice) observations at a contract manufacturer.... ► Artikel lesen | |
| 11.09.25 | XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue increased and fully utilized | 268 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 26.08.25 | Listing of subscription rights and paid subscription shares of XSpray Pharma AB | 360 | GlobeNewswire | With effect from August 27, 2025, the subscription rights of XSpray Pharma AB will be traded on the list for Equity rights. Trading will continue up until and including September 04, 2025.
Instrument:
Subscription... ► Artikel lesen | |
| 25.08.25 | XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue | 368 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 21.08.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 21.08.2025 | 569 | Xetra Newsboard | Das Instrument 6O1 CA13810W1023 CANTER RESOURCES CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 21.08.2025 und ex Kapitalmassnahme am 22.08.2025 The instrument 6O1 CA13810W1023 CANTER RESOURCES... ► Artikel lesen | |
| 19.08.25 | XSpray Pharma AB: Xspray Pharma Submits XS003 to the FDA - The Company's Second Product Candidate from the HyNap Platform | 481 | GlobeNewswire (Europe) | Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 15.08.25 | XSpray Pharma AB: Interim Report Second Quarter 2025 | 244 | GlobeNewswire (Europe) | April-June 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -44,885 thousand (-53,620)Earnings per share before dilution amounted to SEK -2.35 (-1.64)Cash flow... ► Artikel lesen | |
| 12.08.25 | Xspray Pharma Signs License Agreement With Handa Therapeutics For Dasatinib Product | 1 | RTTNews | ||
| 12.08.25 | XSpray Pharma AB: Xspray Pharma signs license agreement with Handa Therapeutics - to receive up to double-digit royalty on Handa's net proceeds | 258 | GlobeNewswire (Europe) | Xspray Pharma ("Xspray") has entered into a license agreement with Handa Therapeutics ("Handa") granting Handa a non-exclusive license to certain Xspray patents. The license covers commercialization... ► Artikel lesen | |
| 11.07.25 | XSpray Pharma AB: XSpray Pharma achieves significant milestone - demonstrating bioequivalence with absorption advantages compared to Tasigna | 214 | GlobeNewswire (Europe) | Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ahead of submitting a New Drug Application (NDA) for the product candidate... ► Artikel lesen | |
| 27.06.25 | XSpray Pharma AB: Xspray Pharma Passes FDA Pre-Approval Inspection - Key Regulatory Milestone Achieved for Dasynoc | 515 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has conducted a successful Pre-Approval Inspection (PAI) of the company's manufacturing lines, located at a contract... ► Artikel lesen | |
| 14.05.25 | XSpray Pharma AB: FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc | 395 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has acknowledged receipt of Xspray Pharma's re-submitted NDA (New Drug Application) for Dasynoc®. The re-submission is based on a CRL (Complete Response Letter)... ► Artikel lesen | |
| 13.05.25 | XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) | 179 | GlobeNewswire (Europe) | The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 13 May 2025.
Adoption of income statement and balance sheet for the financial... ► Artikel lesen | |
| 07.05.25 | XSpray Pharma AB: Interim Report First Quarter 2025 | 252 | GlobeNewswire (Europe) | January - March 2025, Group• Net sales amounted to SEK 0 thousand (0)• Earnings before tax amounted to SEK -42,321 thousand (-67,781)• Earnings per share before dilution amounted to SEK -1.14 (-2.17)•... ► Artikel lesen | |
| 08.04.25 | XSpray Pharma AB: Xspray Pharma re-submits its FDA application | 366 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc®, the company's lead product candidate, an amorphous dasatinib for the treatment of leukemia. The application... ► Artikel lesen | |
| 12.02.25 | XSpray Pharma AB: Interim Report Fourth Quarter 2024 | 195 | GlobeNewswire (Europe) | October-December 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,002 thousand (-54,513)Earnings per share before dilution amounted to SEK -2.36 (-1.85)Cash flow... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,400 | 0,00 % | SpyGlass Pharma Prices IPO At $16 Per Share | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen |
Das Unternehmen XSPRAY PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,205 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.